Investors of ESSA Pharma Inc. Can Join Securities Fraud Class Action Ahead of March Deadline

Join the Class Action Against ESSA Pharma Inc.

Investors who purchased securities of ESSA Pharma Inc. (NASDAQ: EPIX) between December 12, 2023, and October 31, 2024, are reminded of an important deadline for a potential class action lawsuit against the company. The Rosen Law Firm, a leading global firm specializing in investor rights, has announced that the deadline for filing as a lead plaintiff is March 25, 2025.

This class action arises from allegations of securities fraud, with investors claiming that ESSA Pharma misled them regarding the efficacy of its drug, masofaniten, used in combination with enzalutamide for treating prostate cancer. The lawsuit asserts that during the class period, the company failed to inform investors about significant information, including:

1. Lack of Efficacy: That masofaniten, when combined with enzalutamide, did not demonstrate a clear efficacy advantage compared to enzalutamide alone.
2. Misleading Statements: The management's claims about masofaniten's effectiveness and its potential to meet key clinical endpoints were overblown, leading investors to believe in unreasonable expectations.
3. Study Outcomes: Concerns that the critical M-E Combination Study was unlikely to reach its primary endpoint, further diminishing its purported clinical benefits.

When these discrepancies came to light, impacted investors suffered financial damages due to the decline in stock value as the reality of ESSA's performance became evident.

Taking Action

If you believe you are eligible to participate in the class action, it's crucial to act promptly. Investors can join the ESSA Pharma class action by visiting Rosen Law Firm's website at rosenlegal.com or by reaching out to Phillip Kim, Esq., at 866-767-3653. This firm promises to represent investors without upfront fees, working on a contingency basis, meaning that no costs will be incurred unless a recovery is achieved.

Why Choose Rosen Law Firm?

Rosen Law Firm embodies a strong reputation among investor rights firms, known for its successful track record in securities class actions. The team has achieved significant settlements, including the largest at the time against a Chinese company. In 2019 alone, it recovered over $438 million for investors. Their dedication to providing quality legal representation is backed by rankings, including the top position for securities class action settlements in several years by ISS Securities Class Action Services.

Stay Informed

As this situation develops, it's essential for current and potential investors to stay informed through reliable channels. Follow Rosen Law Firm for updates on LinkedIn and Twitter, as they continue to advocate for investor rights and enhance transparency within the securities marketplace.

In conclusion, if you are an ESSA Pharma investor who acquired securities during the defined period, consider joining this class action to hold the company accountable for its actions. For assistance and more information, don’t hesitate to contact Rosen Law Firm directly.

Disclaimer: Please be advised that no class has yet been certified, and individuals are not represented by the firm unless they retain counsel. Always review your options carefully, and you may also choose to remain an absent class member without action if that is your preference.